Immunitybio Inc
NASDAQ:IBRX

Watchlist Manager
Immunitybio Inc Logo
Immunitybio Inc
NASDAQ:IBRX
Watchlist
Price: 2.76 USD -3.83% Market Closed
Market Cap: 2.4B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+67%
Revenue
Forecast
+18%
Operating Income
Forecast
+78%
Net Income
Forecast
N/A

Wall Street
Price Targets

IBRX Price Targets Summary
Immunitybio Inc

Wall Street analysts forecast IBRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IBRX is 11.63 USD with a low forecast of 5.05 USD and a high forecast of 31.5 USD.

IBRX Lowest Forecast
Wall Street Target
5.05 USD
83% Upside
IBRX Average Forecast
Wall Street Target
11.63 USD
321% Upside
IBRX Highest Forecast
Wall Street Target
31.5 USD
1 041% Upside
Lowest
Price Target
5.05 USD
83% Upside
Average
Price Target
11.63 USD
321% Upside
Highest
Price Target
31.5 USD
1 041% Upside
Immunitybio Inc Competitors:
Price Targets
300009
Anhui Anke Biotechnology Group Co Ltd
33% Upside
002252
Shanghai RAAS Blood Products Co Ltd
6% Upside
X
688278
Xiamen Amoytop Biotech Co Ltd
43% Upside
CSL
CSL Ltd
34% Upside
300009
Anhui Anke Biotechnology Group Co Ltd
33% Upside
002252
Shanghai RAAS Blood Products Co Ltd
6% Upside
X
688278
Xiamen Amoytop Biotech Co Ltd
43% Upside
CSL
CSL Ltd
34% Upside
300676
BGI Genomics Co Ltd
11% Upside
OPK
OPKO Health Inc
148% Upside
ARQT
Arcutis Biotherapeutics Inc
50% Upside
688331
RemeGen Co Ltd
30% Downside

Revenue
Forecast

Revenue Estimate
Immunitybio Inc

For the last 8 years the compound annual growth rate for Immunitybio Inc's revenue is 109%. The projected CAGR for the next 3 years is 293%.

109%
Past Growth
293%
Estimated Growth
Estimates Accuracy
60%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Immunitybio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Immunitybio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-71%
Average Miss
What are analyst estimates?

See Also

Summary
IBRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IBRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IBRX stock valuation using valuation multiples.
Wall Street Estimates
IBRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IBRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IBRX's stock price target?
Price Target
11.63 USD

According to Wall Street analysts, the average 1-year price target for IBRX is 11.63 USD with a low forecast of 5.05 USD and a high forecast of 31.5 USD.

What is Immunitybio Inc's Revenue forecast?
Projected CAGR
293%

For the last 8 years the compound annual growth rate for Immunitybio Inc's revenue is 109%. The projected CAGR for the next 3 years is 293%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.